February 25, 2021 The Year 2020 Marks the 7th Consecutive Year Certara Customers Received 90 Percent of US FDA Novel Drug and Biologic Approvals
February 17, 2021 Certara to Report Fourth Quarter and Full Year 2020 Preliminary Financial Results on March 4, 2021
February 5, 2021 Certara Publishes White Paper on Leveraging Biosimulation to Optimize COVID-19 Vaccines
January 27, 2021 Certara Releases Simcyp™ PBPK Simulator Version 20, Including Newly Expanded Biologics Software
December 16, 2020 Certara Announces Closing of its Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
October 27, 2020 Certara Announces Strategic Initiatives to Bolster Clinical Trial Transparency and Disclosure Services